AI tumor board review for genitourinary cancers
A GU tumor board review for each patient
Every perspective. Every disagreement.Every source.
Delibera gives the physician treating GU cancer (prostate to start, bladder and kidney next) a written review from every specialty on the board: every position in its own words, where they disagree, the evidence behind them, and what the record still needs.
Each position is written by an AI model configured to one specialty, so the treating physician sees how every discipline weighs the case.
Who it is for
For the physicians who treat GU cancer close to home
Their patients get the structure of a multidisciplinary board from the physician they already see.
- Urologists and oncologists in community practice
- Every discipline’s reasoning on a case, in writing, before the plan is set.
- Practices that refer to academic centers
- The review can travel with the referral, so the receiving team starts from every discipline’s position and the questions still open.
What it is
A written deliberation summary for each patient
One document per case, laid out the way a tumor board works through it.
- The case as the records state it, with every gap marked and none filled in.
- Each specialty’s position in its own words, and where it disagreed with another.
- What the record still needs, and what to do under each possible answer.
- Every source the board drew on, marked by how it was used, with a link to each.
Clinical deliberation summary · Decision support, not a clinical decision · Research-drafted — not clinician-verified
Delibera · GU Tumor Board · Deliberation Summary
70-year-old Grade Group 2 prostate cancer
Primary recommendation
No definitive call until serum testosterone, prior-therapy timeline, and formal cM adjudication return — then treat as conditional framework below.
Medical Oncologist
Where this specialty disagreed
- Partial agreementwith Radiologist: Agree that imaging shows progression and suspicious para-aortic disease, but disagree with describing this as CHAARTED high-volume disease.
- Dissentwith Nuclear Medicine: The PSMA read is useful, but present-tense RLT eligibility is premature and wrong for the unresolved disease state.
Why a board
Every perspective, before the plan is set
- GU cancers often have more than one reasonable path, and each specialty weighs them differently. A tumor board exists to put those views side by side before anyone commits.
- A split is information. Delibera records who disagreed and why, instead of averaging the difference away.
- For the practice, that means keeping the complex cases you can treat and sending better-prepared referrals for the ones you can’t.
- Delibera is clinical decision support. The treating physician makes the call, and every position shows its basis so it can be checked independently.
How it works
From the records to the summary, in four steps
- 1Add the recordsClinic notes, pathology, imaging reports and labs, or the case in your own words.
- 2Confirm the chartCheck each value against its source, and settle every gap before anything runs.
- 3Run the boardEach specialty forms a position on the confirmed record, then answers the others.
- 4Read the summaryPositions, disagreements, evidence and next steps, in one document.
Why here
In the WWAMI region, specialty GU cancer care can be a flight away
55%
of out-of-state patients surveyed after an in-person urologic cancer visit at Fred Hutch had flown to get there, and 60% needed a hotel
1 in 3
of those patients spent more than $800 on travel for that one visit
About 17,500
new prostate, bladder and kidney cancer cases expected across the five WWAMI states in 2026
Fred Hutch draws urologic cancer patients from across the Northwest, and its own researchers have measured what the trip costs them. Delibera puts every discipline’s reasoning in front of the treating physician first, so the cases that can be settled close to home are, and the ones that need to travel arrive with the open questions already written down. We are starting here, where we live.
Access is by request
Tell us about your practice. We read every request and will get back to you within two business days.
Request access